Abbott Labs (NYS: ABT) announced in an SEC filing Thursday that a phase 3 study of its bardoxolone drug for kidney disease and type 2 diabetes would be halted.
The study's Independent Data Monitoring Committee made the recommendation to stop because of safety concerns due to "excess serious adverse events and mortality in the bardoxolone methyl arm." Abbott's partner on the trial, Reata Pharmaceuticals, made the decision to discontinue the trial. Regulatory authorities and study participants are being notified.
Abbott and Reata say they will will examine the data to determine "whether there is an appropriate path forward for the development of bardoxolone methyl in chronic kidney disease or other indications."
Some had predicted the drug could be a blockbuster.
The bad news for Abbott comes on the heels of a bland quarterly earnings report. The company's third quarter earnings missed on revenue estimates despite beating projected earnings.
The article Safety Concerns Halt Abbott Study of Bardoxolone originally appeared on Fool.com.Dan Carroll has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.